
DXR Valuation
Daxor Corp
DXR Relative Valuation
DXR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, DXR is overvalued; if below, it's undervalued.
Historical Valuation
Daxor Corp (DXR) is now in the Undervalued zone, suggesting that its current forward PS ratio of 12.76 is considered Undervalued compared with the five-year average of 17.12. The fair price of Daxor Corp (DXR) is between 22.56 to 350.55 according to relative valuation methord. Compared to the current price of 12.76 USD , Daxor Corp is Undervalued By 43.44%.
Relative Value
Fair Zone
22.56-350.55
Current Price:12.76
43.44%
Undervalued
2.55
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
Daxor Corp. (DXR) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 13.96. The thresholds are as follows: Strongly Undervalued below -36.96, Undervalued between -36.96 and -11.50, Fairly Valued between 39.41 and -11.50, Overvalued between 39.41 and 64.87, and Strongly Overvalued above 64.87. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
EV/EBIT
Daxor Corp. (DXR) has a current EV/EBIT of 0.00. The 5-year average EV/EBIT is 5.98. The thresholds are as follows: Strongly Undervalued below -17.51, Undervalued between -17.51 and -5.76, Fairly Valued between 17.73 and -5.76, Overvalued between 17.73 and 29.48, and Strongly Overvalued above 29.48. The current Forward EV/EBIT of 0.00 falls within the Historic Trend Line -Fairly Valued range.
12.76
PS
Daxor Corp. (DXR) has a current PS of 12.76. The 5-year average PS is 231.47. The thresholds are as follows: Strongly Undervalued below -178.48, Undervalued between -178.48 and 26.49, Fairly Valued between 436.45 and 26.49, Overvalued between 436.45 and 641.42, and Strongly Overvalued above 641.42. The current Forward PS of 12.76 falls within the Undervalued range.
0.00
P/OCF
Daxor Corp. (DXR) has a current P/OCF of 0.00. The 5-year average P/OCF is -6.96. The thresholds are as follows: Strongly Undervalued below -34.25, Undervalued between -34.25 and -20.61, Fairly Valued between 6.68 and -20.61, Overvalued between 6.68 and 20.33, and Strongly Overvalued above 20.33. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/FCF
Daxor Corp. (DXR) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/FCF of 0.00 falls within the Strongly Undervalued range.
Daxor Corp (DXR) has a current Price-to-Book (P/B) ratio of 1.79. Compared to its 3-year average P/B ratio of 1.36 , the current P/B ratio is approximately 31.26% higher. Relative to its 5-year average P/B ratio of 1.88, the current P/B ratio is about -4.81% higher. Daxor Corp (DXR) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -3.79%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -4.21% , the current FCF yield is about -100.00% lower.
1.79
P/B
Median3y
1.36
Median5y
1.88
2.09
FCF Yield
Median3y
-3.79
Median5y
-4.21
Competitors Valuation Multiple
The average P/S ratio for DXR's competitors is 6.69, providing a benchmark for relative valuation. Daxor Corp Corp (DXR) exhibits a P/S ratio of 12.76, which is 90.73% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Performance Decomposition
1Y
3Y
5Y
Market capitalization of DXR increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of DXR in the past 1 year is driven by Unknown.
People Also Watch

INTZ
Intrusion Inc
1.720
USD
-2.82%

NXL
Nexalin Technology Inc
1.250
USD
-5.30%

FCUV
Focus Universal Inc
3.970
USD
-3.17%

TPST
Tempest Therapeutics Inc
9.540
USD
-4.12%

CMMB
Chemomab Therapeutics Ltd
2.580
USD
-3.37%

KPLT
Katapult Holdings Inc
10.140
USD
-9.55%

IZEA
IZEA Worldwide Inc
4.890
USD
-1.21%

SCNX
Scienture Holdings Inc
0.748
USD
-4.59%
FAQ
Is Daxor Corp (DXR) currently overvalued or undervalued?
Daxor Corp (DXR) is now in the Undervalued zone, suggesting that its current forward PS ratio of 12.76 is considered Undervalued compared with the five-year average of 17.12. The fair price of Daxor Corp (DXR) is between 22.56 to 350.55 according to relative valuation methord. Compared to the current price of 12.76 USD , Daxor Corp is Undervalued By 43.44% .








